Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.

Sathyanarayana P, Jogi M, Muthupillai R, Krishnamurthy R, Samson SL, Bajaj M

Obesity (Silver Spring, Md.)9 Jun 2011Cited by 102 (Europe PMC)

PMID21660077DOI10.1038/oby.2011.152PepBankPUB-21660077

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In type 2 diabetes, added exenatide increased adiponectin more than pioglitazone alone.
In plain wordsIn type 2 diabetes, added exenatide increased adiponectin more than pioglitazone alone.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseAdiponectin
Study
n = 21
Comparator
pioglitazone alone
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 µg twice daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Adiponectin change
193%
combined therapy
Source sentences
Summary
Combined pioglitazone and exenatide therapy was associated with a significantly greater increase in plasma adiponectin (Δ = 193%) and a significantly greater decrease in hepatic fat (12.1 ± 1.7 to 4.7 ± 1.3%) and plasma triglyceride (38%) vs. pioglitazone therapy despite the lack of a significant ch…
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-one T2DM patients (age = 52 ± 3 years, BMI = 32.0 ± 1.5, hemoglobin A(1c) (HbA(1c)) = 8.2 ± 0.4%) on diet and/or metformin received additional treatment with either pioglitazone 45 mg/day for 12 months (n = 10) or combined therapy with pioglitazone (45 mg/day) and exenatide (10 µg subcutaneou…
Report a problemFND-2166007701
02HumanNon-randomized trialEfficacy outcome
In type 2 diabetes, added exenatide reduced hepatic fat more than pioglitazone alone.
In plain wordsIn type 2 diabetes, added exenatide reduced liver fat more than pioglitazone alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseHepatic fat
Study
n = 21
Comparator
pioglitazone alone
Outcome group
Liver fat and liver function · Liver
Studied dose
10 µg twice daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Hepatic fat
12.1%
combined therapy baseline
Hepatic fat
4.7%
combined therapy follow-up
Source sentences
Summary
Combined pioglitazone and exenatide therapy was associated with a significantly greater increase in plasma adiponectin (Δ = 193%) and a significantly greater decrease in hepatic fat (12.1 ± 1.7 to 4.7 ± 1.3%) and plasma triglyceride (38%) vs. pioglitazone therapy despite the lack of a significant ch…
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-one T2DM patients (age = 52 ± 3 years, BMI = 32.0 ± 1.5, hemoglobin A(1c) (HbA(1c)) = 8.2 ± 0.4%) on diet and/or metformin received additional treatment with either pioglitazone 45 mg/day for 12 months (n = 10) or combined therapy with pioglitazone (45 mg/day) and exenatide (10 µg subcutaneou…
Report a problemFND-2166007702
03HumanNon-randomized trialEfficacy outcome
In type 2 diabetes, added exenatide reduced triglycerides more than pioglitazone alone.
In plain wordsIn type 2 diabetes, added exenatide reduced triglycerides more than pioglitazone alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePlasma triglycerides
Study
n = 21
Comparator
pioglitazone alone
Outcome group
Lipids · Metabolic and weight
Studied dose
10 µg twice daily · subcutaneous · 12 monthsAs given in this study (human).
Measurements
Triglyceride decrease
38%
combined therapy
Source sentences
Summary
Combined pioglitazone and exenatide therapy was associated with a significantly greater increase in plasma adiponectin (Δ = 193%) and a significantly greater decrease in hepatic fat (12.1 ± 1.7 to 4.7 ± 1.3%) and plasma triglyceride (38%) vs. pioglitazone therapy despite the lack of a significant ch…
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-one T2DM patients (age = 52 ± 3 years, BMI = 32.0 ± 1.5, hemoglobin A(1c) (HbA(1c)) = 8.2 ± 0.4%) on diet and/or metformin received additional treatment with either pioglitazone 45 mg/day for 12 months (n = 10) or combined therapy with pioglitazone (45 mg/day) and exenatide (10 µg subcutaneou…
Report a problemFND-2166007703
04HumanNon-randomized trialEfficacy outcome
In type 2 diabetes, added exenatide reduced ALT more than pioglitazone alone.
In plain wordsIn type 2 diabetes, added exenatide reduced the liver injury marker ALT more than pioglitazone alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAlanine aminotransferase
Study
n = 21
Comparator
pioglitazone alone
Outcome group
Liver fat and liver function · Liver
Studied dose
10 µg twice daily · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Summary
Hepatic injury biomarkers aspartate aminotransferase and alanine aminotransferase (ALT) were significantly decreased by both treatments; however, the reduction in ALT was significantly greater following combined pioglitazone and exenatide therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-one T2DM patients (age = 52 ± 3 years, BMI = 32.0 ± 1.5, hemoglobin A(1c) (HbA(1c)) = 8.2 ± 0.4%) on diet and/or metformin received additional treatment with either pioglitazone 45 mg/day for 12 months (n = 10) or combined therapy with pioglitazone (45 mg/day) and exenatide (10 µg subcutaneou…
Report a problemFND-2166007706

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

05HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome
In type 2 diabetes, combined pioglitazone and exenatide produced no significant change in body weight.
In plain wordsIn type 2 diabetes, combined pioglitazone and exenatide did not significantly change body weight.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBody weight
Study
n = 11
Comparator
baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Weight change
0.2 kg
combined therapy
Source sentences
Summary
Combined pioglitazone and exenatide therapy was associated with a significantly greater increase in plasma adiponectin (Δ = 193%) and a significantly greater decrease in hepatic fat (12.1 ± 1.7 to 4.7 ± 1.3%) and plasma triglyceride (38%) vs. pioglitazone therapy despite the lack of a significant ch…
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-one T2DM patients (age = 52 ± 3 years, BMI = 32.0 ± 1.5, hemoglobin A(1c) (HbA(1c)) = 8.2 ± 0.4%) on diet and/or metformin received additional treatment with either pioglitazone 45 mg/day for 12 months (n = 10) or combined therapy with pioglitazone (45 mg/day) and exenatide (10 µg subcutaneou…
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2166007704
06HumanNot a test of Exenatide (exendin-4) aloneNon-randomized trialEfficacy outcome
In type 2 diabetes, combined pioglitazone and exenatide reduced aspartate aminotransferase, as did pioglitazone alone.
In plain wordsIn type 2 diabetes, combined pioglitazone and exenatide reduced aspartate aminotransferase, as did pioglitazone alone.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseAspartate aminotransferase
Study
n = 11
Comparator
baseline
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
Hepatic injury biomarkers aspartate aminotransferase and alanine aminotransferase (ALT) were significantly decreased by both treatments; however, the reduction in ALT was significantly greater following combined pioglitazone and exenatide therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
Twenty-one T2DM patients (age = 52 ± 3 years, BMI = 32.0 ± 1.5, hemoglobin A(1c) (HbA(1c)) = 8.2 ± 0.4%) on diet and/or metformin received additional treatment with either pioglitazone 45 mg/day for 12 months (n = 10) or combined therapy with pioglitazone (45 mg/day) and exenatide (10 µg subcutaneou…
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2166007705

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02303730

Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

Fudan Universityn = 76Mar 2015 to Nov 2017

Diabetes Mellitus, Type 2 · Non-alcoholic Fatty Liver Disease

Trial page ClinicalTrials.govUpdated 28 Aug 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.